M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Magic pills: new oral drugs to treat chronic lymphocytic leukemia
TL;DR: Novel oral drugs represent a valuable alternative to chemo-immunotherapy for patients with CLL, especially when high-risk disease features are present and when age or comorbidities preclude the use of standard treatments.
Journal ArticleDOI
Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints.
Antonio Palumbo,Pellegrino Musto,Tommaso Caravita,Alessandra Larocca,Davide Rossi,Dina Ben Yehuda,Massimo Offidani,Francesca De' Donato,Paola Finsinger,Paola Omedè,Concetta Conticello,Arnon Nagler,Roberto Ria,Maide Cavalli,Roberto Mina,Maria Teresa Petrucci,Izhar Hardan,Federica Cavallo,Mario Boccadoro +18 more
TL;DR: Evaluated PFS1, PFS2 and OS in newly diagnosed multiple myeloma (NDMM) patients who received CT or FDT, finding that continuous therapy significantly prolongs remission duration and resistant relapse may reduce the duration of subsequent remission.
Journal ArticleDOI
Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study
Michele Cavo,Monica Galli,Annalisa Pezzi,Francesco Di Raimondo,Claudia Crippa,Massimo Offidani,Paola Tacchetti,Vittorio Montefusco,Franco Narni,Antonio Spadano,Norbert Pescosta,Elena Zamagni,Barbara Gamberi,Tommaso Caravita,Antonietta Falcone,Chiara Nozzoli,Renato Zambello,Anna Furlan,Annamaria Brioli,Mario Boccadoro +19 more
TL;DR: An initial divergence between OS curves could be appreciated after 4 years, although the difference was not yet statistically significant at 6 years, and Superiority of VTD over TD for TTP and PFS was retained across prespecified subgroups of patients with high risk and low risk disease.
Journal ArticleDOI
Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis.
Carmela Attisano,Alberto Bianchi,Laura Montacchini,Nadia Carlesso,Silvia Peola,Benedetto Bruno,Viviana Roux,Dario Ferrero,Eugenio Gallo,Mario Boccadoro,Alessandro Pileri,Massimo Massaia +11 more
TL;DR: Investigation of the effect of OKT3 stimulation in vitro on autologous haemopoietic progenitor cells (HPC) of MM patients found it suppressed erythroid burst‐forming units (BFU‐E and CFU‐GM generation from HPC responsible for long‐term maintenance of in vitro myelopoiesis.
Journal ArticleDOI
FLAI induction regimen in elderly patients with acute myeloid leukemia.
Marco Cerrano,Anna Candoni,Elena Crisà,Maria Vittoria Dubbini,Stefano D'Ardia,Maria Elena Zannier,Mario Boccadoro,Ernesta Audisio,Benedetto Bruno,Dario Ferrero +9 more
TL;DR: This book aims to provide a history of Oncology and Hematology in Italy from 1950 to 1990, a period chosen in order to explore the role ofbestos in the development of cancer and its role in the immune system.